Related Experiment Video
Updated: Aug 13, 2026

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
Published on: January 6, 2014
Prophylactic cancer vaccines
1Department of Immunology, University of Pittsburgh School of Medicine and University of Pittsburgh Cancer Institute, W1142 Biomedical Science Tower, Pittsburgh, PA 15261, USA. ojfinn@pitt.edu
Abstract:
Increasingly, data from distinct experimental systems show that immunity can be activated to prevent tumors. The rationale for prevention is strong because, in that setting, one deals with an immune system that is neither impaired by tumor- and treatment-induced suppression nor tolerant to tumor-associated antigens that have been encountered in the absence of correct presentation and costimulatory/danger signals. The use of overexpressed or mutated proteins, or mutated oncogenic growth factor receptors, as tumor-associated antigens yields rational targets for specific immunoprevention. Transgenic mouse models are providing encouraging indications of future usefulness of vaccines that are based on these molecules.
Insights
Activating immunity can prevent tumors by targeting specific antigens. This approach leverages a robust immune system for effective cancer immunoprevention, showing promise in preclinical models.
Area of Science:
- Immunology
- Oncology
- Vaccinology
Background:
- Distinct experimental systems indicate that activating the immune system can prevent tumor development.
- The immune system is more effective for prevention as it is not suppressed by tumors or treatments and is not tolerant to antigens.
- Tumor-associated antigens, including overexpressed/mutated proteins and oncogenic receptors, offer rational targets for specific immunoprevention.
Purpose of the Study:
- To explore the potential of activating immunity for cancer immunoprevention.
- To identify and utilize specific tumor-associated antigens as targets for preventive vaccines.
- To evaluate the efficacy of immunoprevention strategies using preclinical models.
Main Methods:
- Utilizing distinct experimental systems to study immune activation against tumors.
- Identifying and characterizing tumor-associated antigens (overexpressed proteins, mutated proteins, mutated oncogenic growth factor receptors).
- Employing transgenic mouse models to test vaccine strategies based on identified antigens.
Main Results:
- Data suggest that immunity can be successfully activated to prevent tumors.
- The immune system's state in the absence of tumor burden and treatment is favorable for immunoprevention.
- Transgenic mouse models show promising results for vaccines targeting specific antigens.
Conclusions:
- Immune system activation presents a viable strategy for cancer immunoprevention.
- Targeting specific tumor-associated antigens is a rational approach for developing preventive vaccines.
- Preclinical data from mouse models support the future utility of antigen-based vaccines for cancer prevention.
More Related Videos
Related Concept Videos
Cancer Prevention
Some...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Preventive Healthcare Services
Cancer Prevention
Some...
Tumor Immunotherapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

